Oxbow Advisors LLC continued to hold its stake in Merck & Company, Inc. (NYSE:MRK) during the second quarter, according to its most recent filing with the SEC. The fund owned 11,495 shares of the company’s stock at the end of the second quarter. Oxbow Advisors LLC’s holdings in Merck & were worth $737,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the company. Boston Partners boosted its stake in shares of Merck & by 2.6% in the first quarter. Boston Partners now owns 19,935,016 shares of the company’s stock worth $1,266,671,000 after buying an additional 500,476 shares during the period. Clearbridge Investments LLC boosted its stake in shares of Merck & by 0.6% in the first quarter. Clearbridge Investments LLC now owns 13,414,669 shares of the company’s stock worth $852,368,000 after buying an additional 77,344 shares during the period. Sanders Capital LLC boosted its stake in shares of Merck & by 3.3% in the first quarter. Sanders Capital LLC now owns 11,593,645 shares of the company’s stock worth $752,482,000 after buying an additional 365,276 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Merck & by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 9,821,563 shares of the company’s stock worth $624,064,000 after buying an additional 41,748 shares during the period. Finally, Bank of Montreal Can boosted its stake in shares of Merck & by 8.1% in the second quarter. Bank of Montreal Can now owns 9,723,813 shares of the company’s stock worth $623,199,000 after buying an additional 732,720 shares during the period. 73.00% of the stock is owned by institutional investors and hedge funds.

Shares of Merck & Company, Inc. (NYSE:MRK) traded up 0.49% on Thursday, hitting $63.43. 5,112,531 shares of the stock were exchanged. The firm’s 50 day moving average price is $62.73 and its 200 day moving average price is $63.80. The firm has a market cap of $173.00 billion, a price-to-earnings ratio of 34.34 and a beta of 0.80. Merck & Company, Inc. has a one year low of $58.29 and a one year high of $66.80.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. Merck &’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the firm posted $0.93 EPS. Equities analysts anticipate that Merck & Company, Inc. will post $3.88 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.98%. Merck &’s dividend payout ratio is presently 76.11%.

WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/31/oxbow-advisors-llc-has-737000-position-in-merck-company-inc-mrk.html.

MRK has been the subject of a number of research reports. J P Morgan Chase & Co boosted their price target on shares of Merck & from $74.00 to $76.00 and gave the company an “overweight” rating in a research report on Thursday, May 11th. Zacks Investment Research cut shares of Merck & from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Credit Suisse Group reissued a “buy” rating on shares of Merck & in a research report on Tuesday, June 13th. Vetr raised shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 price target for the company in a research report on Monday, May 15th. Finally, Cowen and Company reissued a “market perform” rating and issued a $70.00 price target (up from $68.00) on shares of Merck & in a research report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $69.74.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.